Veradermics, Incorporated (MANE) - Cash Flow Conversion Efficiency

Latest as of March 2026: -0.054x

Based on the latest financial reports, Veradermics, Incorporated (MANE) has a cash flow conversion efficiency ratio of -0.054x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-21.17 Million) by net assets ($391.87 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Veradermics, Incorporated defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.

Veradermics, Incorporated - Cash Flow Conversion Efficiency Trend (2023–2025)

This chart illustrates how Veradermics, Incorporated's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Veradermics, Incorporated Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Veradermics, Incorporated ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Beijing Roborock Technology Co Ltd
SHG:688169
-0.014x
JB Chemicals & Pharmaceuticals Limited
NSE:JBCHEPHARM
0.087x
Zhejiang Shenghua Biok Biology Co Ltd
SHG:600226
0.021x
Badger Meter Inc
NYSE:BMI
0.049x
Inner Mongolia ERDOS Resources Co Ltd
SHG:600295
0.036x
Zhefu Holding Group Co Ltd
SHE:002266
-0.056x
Appfolio Inc
NASDAQ:APPF
0.073x
MINISO GRP HLD.ADS/4
F:MIF
N/A

Annual Cash Flow Conversion Efficiency for Veradermics, Incorporated (2023–2025)

The table below shows the annual cash flow conversion efficiency of Veradermics, Incorporated from 2023 to 2025. For the full company profile with market capitalisation and key ratios, see MANE stock market capitalisation.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 $-121.01 Million $-71.60 Million 0.592x +236.54%
2024-12-31 $54.66 Million $-23.69 Million -0.433x +53.11%
2023-12-31 $14.62 Million $-13.51 Million -0.924x --

About Veradermics, Incorporated

NYSE:MANE USA Biotechnology
Market Cap
$3.80 Billion
Market Cap Rank
#4344 Global
#1464 in USA
Share Price
$90.95
Change (1 day)
-5.53%
52-Week Range
$37.03 - $114.80
All Time High
$114.80
About

Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy. Additionally, it engages in t… Read more